# Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes

> **NCT00575471** · PHASE2 · COMPLETED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 250 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Rivoglitazone HCl
- **DRUG:** rivoglitazone HCl
- **DRUG:** rivoglitazone HCl
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00575471
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2009-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00575471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00575471, "Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00575471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*